Related Experiment Videos
Improved safety and titre of murine leukaemia virus (MLV)-based retroviral vectors
1Department of Immunology, Windeyer Building, 46 Cleveland St, London WIP 6DB, UK.
Gene Therapy
|March 1, 2000
Abstract:
Many retroviral vectors based on murine leukaemia virus (MLV) contain the first 420 nucleotides of the gag gene, as this was reported to increase vector titre by increasing the efficiency of RNA packaging. In this study, deletion of this gag sequence from its original location did not decrease the titre of two retroviral vectors, pBabe puro and MFG-S-. The two vectors could be improved by replacing the gag sequence with a CTE from Mason-Pfizer monkey virus (MPMV). This substitution improved vector titre, while eliminating a region of homology between vector and packaging constructs. Gene Therapy (2000) 7, 300-305.